Revive Therapeutics (RVVTF) provides an update on the Company’s clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy. The Study has enrolled nearly 50% of its intended study sample, with initial efficacy being encouraging. The clinical data generated from the Study may provide proprietary and valuable information on the safety, efficacy and dosing of oral psilocybin to support a potential pivotal clinical study and commercial initiatives in countries, such as Australia, where psilocybin can be available to licensed psychiatrists to prescribe for certain conditions. In addition, the Company will have exclusive access to key intellectual property from this Study to support commercial and development initiatives, including future clinical studies for its proposed novel delivery of psilocybin by a proprietary microneedle patch under its research collaboration agreement with PharmaTher (PHRRF) for neuropsychiatric disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVVTF:
- Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
- Revive Therapeutics Eyes FDA Approval for COVID Treatment
- Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
- Revive Therapeutics submits Type C meeting request package to FDA
- Revive Therapeutics Advances Bucillamine for Long COVID